COVID-19 vaccine reaches phase-2 trials in China
Xinhua |
Updated: 2020-06-20 21:11
Share
Share - WeChat
BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- Autumn harvest in China
- HKSAR govt activates emergency monitoring and support center for typhoon Ragasa
- South China's Guangdong raises emergency response to highest for approaching typhoon
- Northern Myanmar criminal group on trial in China over killings, telecom fraud
- Mongolian party leader lauds Shanghai's community-level services
- Healthier habits can curb gout, doctors say
